secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2021-10-05T23:59:59+00:00
Accession:  0001193125-21-292225
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma closes merger with Strongbridge; appoints new board and officers
--------------------------------------------------------------------------------

- Board expanded from 1 to 8 directors; members include prior directors from Xeris and Strongbridge.
- New officers: John Shannon as President/COO, Kenneth Johnson as SVP Global Development, Beth Hecht as Chief Legal Officer, Steven Prestrelski as Chief Scientific Officer.
- CEO Paul Edick gets amended employment: base salary $667,244, target bonus 60%; severance up to 24 months base upon change-in-control termination.
- COO Shannon base salary $500,000 with 50% target bonus; CFO Pieper base salary $375,000 with 40% target bonus.
- Assumed legacy equity plans from both Xeris (2018 Plan, ESPP, Inducement Plan) and Strongbridge (2015 Plan, Director Plan, 2017 Inducement Plan).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/d184152d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-292225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer